menu search

AVTE / Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market

Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market
AVTE reported Q4 2023 earnings in line with expectations and has enough cash runway until H2 2025. AV-101, AVTE's lead asset, is on track with patient enrollment in phase 2b PAH trial, and top-line Phase 2b data is expected by Q4 '23 or Q1 '24. Read More
Posted: Apr 12 2023, 08:45
Author Name: Seeking Alpha
Views: 122485

AVTE News  

Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market

By Seeking Alpha
April 12, 2023

Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market

AVTE reported Q4 2023 earnings in line with expectations and has enough cash runway until H2 2025. AV-101, AVTE's lead asset, is on track with patient more_horizontal

Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy

By Seeking Alpha
January 29, 2023

Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy

Aerovate is a SMID-cap biotech developing an inhaled imatinib for pulmonary arterial hypertension. AV-101's Phase 2b PAH data is expected in 4Q 2023 o more_horizontal


Search within

Pages Search Results: